BIOMAT Database Logo BIOMAT Database Logo

Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group. 1991

L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Medical College of Virginia, Virginia Commonwealth University, Richmond.

In this 3-year study of suppressive acyclovir for recurrent genital herpes, patients with more than six recurrences per year were randomized initially to 400 mg of acyclovir or placebo orally two times per day, with recurrences treated with 200 mg of acyclovir five times per day for 5 days. In the second year of the study, all patients received acyclovir as a daily suppressive or intermittent acute therapy; in the third year, all received daily acyclovir. Among 525 patients completing 3 study years, 289 received 3 years of suppressive therapy and 236 received 1 year of acute therapy followed by 2 years of suppressive therapy. Of those who completed the third year, 61% were recurrence free that year; 25% of the suppressive therapy-only group were recurrence free for all 3 years. The annual recurrence rate dropped from more than 12 recurrences per year at baseline to 1.0 (suppressive therapy) and 1.4 (acute and suppressive therapy) recurrences during the third year. No significant toxic effects were detected. Daily suppressive acyclovir therapy was effective and well tolerated.

UI MeSH Term Description Entries
D008297 Male Males
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002214 Capsules Hard or soft soluble containers used for the oral administration of medicine. Capsule,Microcapsule,Microcapsules
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006558 Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females. Genital Herpes,Herpes Simplex, Genital,Herpes Simplex Virus Genital Infection,Genital Herpes Simplex,Herpes, Genital
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection.
August 1988, The American journal of medicine,
L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Continuous five-year treatment of patients with frequently recurring genital herpes simplex virus infection with acyclovir.
January 1993, Journal of medical virology,
L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial.
July 1988, JAMA,
L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Chronic-dose acyclovir to suppress frequently recurring genital herpes simplex virus infection: effect on antibody response to herpes simplex virus type 2 proteins.
December 1988, The Journal of infectious diseases,
L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex.
April 1989, Genitourinary medicine,
L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Treatment with acyclovir of genital herpes simplex virus infection complicated by eczema herpeticum.
August 1984, The British journal of venereal diseases,
L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Acyclovir treatment of experimental genital herpes simplex virus infections.
July 1982, The American journal of medicine,
L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Treatment of resistant herpes simplex virus with continuous-infusion acyclovir.
January 1990, JAMA,
L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Long term persistence of herpes simplex virus-specific CD8+ CTL in persons with frequently recurring genital herpes.
July 2000, Journal of immunology (Baltimore, Md. : 1950),
L G Kaplowitz, and D Baker, and L Gelb, and J Blythe, and R Hale, and P Frost, and C Crumpacker, and S Rabinovich, and J E Peacock, and J Herndon
Oral acyclovir for genital herpes simplex infection.
May 1985, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!